(10.1101/2023.02.20.23286191; this version posted February 21, 2023. The copyright holder for this medRxiv preprint doi: https://doi.org/ preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Longitudinal dynamics of Streptococcus pneumoniae carriage and SARS-CoV-2 infection in 1 households with children. 2 3 Willem R. Miellet^{1,2#}, Rob Mariman^{2,}, Dirk Eggink², Mioara A. Nicolaie³, Janieke van Veldhuizen^{2,}, Gerlinde 4 Pluister², Lisa M. Kolodziej⁵, Steven F.L. van Lelyveld⁴, Sjoerd M. Euser⁶, Elisabeth A.M. Sanders^{1,2}, 5 Marianne A. van Houten⁷, Krzysztof Trzciński¹ 6 7 ¹Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University 8 Medical Center Utrecht (UMCU), The Netherlands; 9 ²Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), 10 Bilthoven, The Netherlands; 11 ³Department of Statistics, Data Science and Modelling, National Institute for Public Health and the 12 Environment (RIVM), Bilthoven, The Netherlands; 13 ⁴Department of internal medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands: 14 ⁵Present affiliation: Department of Medical Microbiology and Infection Prevention, Amsterdam University 15 Medical Centres, University of Amsterdam, Amsterdam, The Netherlands; 16 ⁶Regional Public Health Laboratory Kennemerland, Haarlem, The Netherlands; 17 ⁷Department of pediatrics, Spaarne Gasthuis, Haarlem, The Netherlands. 18 19 [#]corresponding author: 20 UMCU, Heidelberglaan 100, HP - G04.614, 3508 AB Utrecht, The Netherlands 21 w.r.miellet-2@umcutrecht.nl 22 Phone: +31 638259782 23 24 25 Running title: Pneumococcus & SARS-CoV-2 dynamics

ABSTRACT 26

27 **Background:**

To characterize interferences between Streptococcus pneumoniae and SARS-CoV-2 we investigated the 28 longitudinal patterns of viral infection and pneumococcal carriage in households infected with SARS-CoV-2. 29

30

31 **Methods:**

SARS-CoV-2 and pneumococcus were detected with quantitative molecular methods in saliva from members 32 of eighty participating households. Samples were collected between October 2020 and January 2021 from 33 n=197 adults and n=118 children of which n=176 adults and n=98 children had a complete set of ten samples 34 collected within 42 days since enrolment. Time-dependent Cox models were used to evaluate the associations 35 between SARS-CoV-2 and pneumococcal carriage. 36

Results: 37

In the entire cohort, cumulative pneumococcal carriage and SARS-CoV-2 infection rates were 58% and 65%, 38 respectively. Pneumococcal abundances were associated with an increased risk of SARS-CoV-2 infection (HR 39 1.14, 95% CI, 1.01 – 1.29, P=0.04) and delayed clearance of SARS-CoV-2 infection (HR 0.90, 95% CI, 0.82 40 -0.99, P=0.03). Elevated viral loads were observed among pneumococcal carriers and individuals with high 41 overall bacterial 16S abundances, however, there were no longitudinal differences in viral loads in linear 42 mixed-effects models. Individuals with high 16S abundances displayed delayed viral clearance (HR 0.65, 95% 43 44 CI 0.55 – 0.78, *P*<0.0001).

45 **Conclusions:**

Although we found insufficient evidence for a strong impact of SARS-CoV-2 infection on pneumococcal 46 carriage. Results from the current study suggest that pneumococcal carriers may have an increased risk of 47 SARS-CoV-2 infection and high pneumococcal abundances and 16S abundances may be associated with 48 elevated viral loads and delayed clearance of SARS-CoV-2 infection. 49

- 50
- Keywords: Streptococcus pneumoniae, pneumococcal carriage, SARS-CoV-2, COVID-19, co-infection 51

INTRODUCTION 52

Epidemiological studies and animal co-infection models suggest strong synergistic interactions between 53 certain respiratory viruses and *Streptococcus pneumoniae* [1]. For one, influenza virus, respiratory syncytial 54 virus, and rhinovirus provoke host immune responses that can disturb colonizing resistance induced by the 55 microbiota of the upper respiratory tract (URT), mute innate immune recognition of pneumococcus and 56 57 increase the risk of secondary pneumococcal pneumonia [2-8]. Concomitantly, inflammation associated with pneumococcal colonization may facilitate viral respiratory infections [9-12]. 58

Relatively little is known about interferences between pneumococcus and SARS-CoV-2. However, between 59 2020 and 2021 multiple countries reported declines in incidence of invasive pneumococcal disease (IPD) [13-60 15] and co-infections with pneumococcus were rare in COVID-19 patients [14, 16]. Although high rates of 61 empiric antibiotic therapy in severe COVID-19 cases could have diminished pneumococcal disease incidence 62 and contribute to low co-infection rates [17-19], the decline in IPD was primarily attributed to non-63 pharmaceutical interventions (NPIs) [13, 14]. It has been assumed that NPIs that included social distancing, 64 wearing facemasks, closure of schools, restaurants, shops and cultural facilities and the advice to work from 65 home limited pneumococcal transmission, thereby reducing the prevalence of pneumococcal carriage and 66 consequently the incidence of IPD during pandemic [13]. However, several studies have reported that 67 pneumococcal carriage rates in children were relatively unaffected during the pandemic when compared with 68 the pre-COVID-19 period [15, 20]. Danino et al. concluded that declines in pneumococcal disease were likely 69 driven by declines in seasonal respiratory virus circulation and not by reduced pneumococcal transmission 70 [15]. 71

72

73 URT inflammation associated with pneumococcal colonization may facilitate propagation of viral infection in the airways of exposed individuals [9-11]. While few clinical studies have investigated co-infections 74 between SARS-CoV-2 and pneumococcus, none of the published papers have reported on possible 75 interference between the two pathogens within households and studied longitudinal effects. To investigate the 76 effect of pneumococcal colonization on SARS-CoV-2 infection and vice versa, we have conducted a 77 longitudinal household study using molecular diagnostic methods to detect SARS-CoV-2 and pneumococcus 78 in self-collected saliva samples [6, 21]. In our study, we found insufficient evidence for a strong impact of 79 SARS-CoV-2 infection on pneumococcal carriage. However, pneumococcal carriers, children in particular, 80 exhibited an increased risk of SARS-CoV-2 infection. High pneumococcal abundances and 16S abundances 81 were associated with elevated viral loads and delayed clearance of SARS-CoV-2 infection. 82

MATERIALS and METHODS 83

Study Design and Ethics statement 84

We investigated pneumococcal carriage in a prospective observational cohort study [21] conducted between 85 October 2020 and January 2021. Households were included in the study when a household member below 65 86 years of age tested positive for SARS-CoV-2 using qPCR within 72 hours prior to inclusion and at least 2 87 other household members consented to participate in the study. Enrolled study participants were asked to self-88 collect saliva samples over a period of six weeks. Written informed consent was obtained from all study 89 participants or from their legal guardians. The study was reviewed and approved by the Medical Ethical 90 Committee of the Vrije Universiteit university Medical Centre (Vumc), The Netherlands (reference nr. 91 020.436). 92

93

Sample Collection 94

As previously described by Kolodziej *et al.*, saliva samples were collected on day 1, 3, 5, 7, 10, 14, 21, 28, 35, 95 and 42 since inclusion [21]. In short, individuals aged >5 years were asked to collect saliva, by spitting 96 approximately 2 ml into a Genefix Saliva Collection device without buffer (Isohelix). From individuals aged 97 <5 years saliva was collected with two Oracol (S10) sponges (Malvern Medical Developments). Samples were 98 stored by participants in their home freezer and within three weeks transported on dry ice to the diagnostic 99 laboratory for storage at -80°C. 100

101

SARS-CoV-2 and S. pneumoniae detection with quantitative molecular methods 102

Nucleic acids were extracted from 200 µl of saliva using a MagNApure 96 system (Roche) with Equine 103 arteritis virus and yeast tRNA added as internal control and stabilizer, respectively. Nucleic acids were eluted 104 into 50 µl Tris EDTA buffer. To detect SARS-CoV-2, 5 µl of the eluate was tested in reverse-transcriptase 105 qPCR with primers and probe targeting the SARS-like beta coronavirus-specific Egene [22]. Pneumococcal 106 DNA was detected by testing 5.5 µl of a sample in single-plex qPCRs with primers and probes targeting DNA 107 sequences within genes encoding for pneumococcal iron uptake ABC transporter lipoprotein (PiaB) [23], and 108 major pneumococcal autolysin (LytA) [24] as previously described [25]. We quantified 16S with qPCR as a 109 marker of overall bacterial abundance [6]. Molecular detection of pneumococcal serotypes is described in the 110 Supplement. 111

112

Statistical Analysis 113

Data analysis was performed in R version 4.2.2. Samples were considered positive by qPCR for piaB, lytA 114 and Egene when Cas were below 40. For qPCR-based serotyping results concordance with piaB/lytA was 115 required [26]. Intraclass correlations (ICCs (3,1)) were calculated in a two-way mixed-effects model with 116 consistency relationship (*piaB* $C_q = lytA C_q + systematic error)$ and of single measurement type [27], and 117 Bland-Altman plots [28] were used to assess agreement between qPCR measurements using the "irr" and 118 "blandr" R packages, respectively. Unpaired and paired carriage rates were compared with Fisher's exact test 119

and McNemar's test, respectively. Relative pneumococcal abundances were calculated by dividing 120 pneumococcal abundances by overall bacterial abundances (16S). Bacterial and pneumococcal abundances 121 were compared by means of a permutation test equivalent of Mann-Whitney U test with blocking by age group 122 [29]. Linear mixed-effects modeling was conducted to assess the association between SARS-CoV-2 infection 123 and pneumococcal carriage status, and between SARS-CoV-2 infection and 16S abundances, where 124 individuals at time 1 were classified as having low (< median at time 1) or high (> median at time 1) 16S 125 abundance. A random intercept was used in linear-mixed effects model to account for longitudinal intra-126 individual variance, and to address inter-individual variance. The time to SARS-CoV-2 infection and time to 127 SARS-CoV-2 infection clearance in relationship to pneumococcal carriage, pneumococcal abundance and log-128 transformed overall bacterial (16S) abundance were assessed by means of stratified time-dependent Cox 129 proportional hazards models, where strata were defined by age groups. In order to estimate age-specific hazard 130 rates (HR), two age groups were considered, children (<18 years) and adults (>18 years). The proportionality 131 assumption was tested using the Schoenfeld residuals test. Model selection was performed by means of the 132 Akaike information criterion and model checking was done by comparing the model-based survival curves 133 with the Kaplan-Meier estimator. A p value of <0.05 was considered significant. 134

RESULTS 135

Of 337 individuals from whom saliva was collected, 11 had incomplete questionnaire data and 52 fewer than 136 ten samples collected. As such, analysis was limited to 274 (81.3.%) individuals of 80 households (**Table 1**). 137 Sixty-five percent of individuals (177/274) and 95% (76/80) of households tested positive for SARS-CoV-2 138 infection in saliva during the six weeks of screening [21]. Per study design, almost all SARS-CoV-2 infections 139 occurred within the first 10 days since enrolment and the number of SARS-CoV-2 infected individuals began 140 to decline after the first 14 days of the study period [21]. 141

142

Pneumococcal Carriage Prevalence Rates in Households with Individuals Infected with SARS-CoV-2 143

Altogether, 160 individuals (58% of 274) tested positive for pneumococcus by qPCR. This corresponded to 144 40% (1083/2740) of samples positive for pneumococcus using a dual-target approach with *piaB* and *lvtA* 145 genes, with significant correlations between *piaB* and *lytA* C_{0} s (Fig. 1) and ICCs of 0.89 (95% CI 0.87 – 0.90) 146 indicative of good reliability. Similar ICCs were observed at each of the ten sampling events separately (Fig. 147 S1). During a follow-up of six weeks cumulative pneumococcal carriage and SARS-CoV-2 infection rates 148 were 58.4% (160 of 274) and 64.6% (177 of 274), respectively. We observed a mean pneumococcal carriage 149 rate of 35.8% (98/274, 95% CI 30-42%) (Table S1). The proportion of pneumococcal carriers with SARS-150 CoV-2 infection was high during the first two weeks of the study with on average 54.1% of pneumococcal 151 carriers concurrently positive for SARS-CoV-2 and a cumulative co-infection rate of 33.9% (93 of 274). 152 Despite high co-infection rates, pneumococcal carriage rates remained relatively constant throughout the study 153 period (Fig. 2), suggesting little impact of SARS-CoV-2 infection on pneumococcal carriage rates. Rates of 154 pneumococcal carriage were highest among children <12 years of age (88.2%, **Table 1**) and households with 155 young children (<5 years; n=15) displayed significantly increased rates of pneumococcal carriage compared 156 with other households (Fisher's exact test, P<0.0001, OR 7.7 [95% CI 3.1-22.8]). 157

158

Hazards Model Analysis 159

We sought to evaluate the relationship between pneumococcal carriage and SARS-CoV-2 infection. To this 160 goal, only samples from individuals who tested negative at enrolment were considered (n=121 individuals 161 experiencing n=23 virus acquisition events). We fit a Cox proportional hazards model to the time to SARS-162 CoV-2 infection. In a multivariate model, pneumococcal abundances and 16S abundances were used as 163 covariates. To account for events within the same family, we calculated robust standard errors for effects sizes. 164 Next, we performed model selection (Table S2, Fig. S2). Using the multivariable model, pneumococcal 165 abundances were associated with an increased risk for SARS-CoV-2 infection (HR 1.14, 95% CI, 1.01 – 1.29). 166 whereas we did not find sufficient evidence for an association between 16S abundances and SARS-CoV-2 167 infection (HR 0.86, 95% CI, 0.58 - 1.27). The cumulative hazard rates across the study period were higher for 168 children (HR 2.14) than for adults (HR 0.83), suggesting that the relationship between pneumococcal 169 abundances and SARS-CoV-2 infection was primarily associated with children. 170

Next, we assessed the association between pneumococcal carriage and SARS-CoV-2 infection clearance. We 172 therefore limited the analysis to samples from individuals who tested positive for SARS-CoV-2 at enrolment 173 (n=153 individuals experiencing n=134 events) and we used stratified Cox regression analysis to model the 174 time to SARS-CoV-2 infection clearance. Multivariate models that included covariates for pneumococcal 175 abundance and 16S abundance, were considered for model selection (Table S3, Fig. S3). In the multivariable 176 model both pneumococcal abundances (HR 0.90 95% CI, 0.82 – 0.99) and 16S abundances (HR 0.68 95% CI, 177 0.55 - 0.78) before day 21 were significantly associated with a decreased risk for SARS-CoV-2 infection 178 clearance (Table S3). 179

180

181 Pneumococcal abundances among SARS-CoV-2 infected individuals

We then sought to determine whether SARS-CoV-2 infection impacted pneumococcal abundances and 182 bacterial presence in the upper respiratory airways. SARS-CoV-2 infected individuals exhibited significantly 183 elevated pneumococcal abundances at day 10, 21 and 28 when compared with uninfected individuals (Fig. 184 S4A). Likewise, significantly elevated 16S abundances among SARS-CoV-2 infected individuals were 185 observed at day 10, 14, 21 and 28 (Fig. S4B). However, no significant differences between SARS-CoV-2 186 infected and uninfected individuals were observed for pneumococcal relative abundances (Fig. S4C). In line 187 with this, we did not observe considerable shifts in serotype carriage composition across the study period (Fig. 188 S5). 189

190

191 Increased viral loads in individuals carrying pneumococcus

Thereafter, we quantified *Egene* as a marker of SARS-CoV-2 viral loads from individuals who tested positive 192 for SARS-CoV-2 at enrolment and compared viral loads among pneumococcal carriers and noncarriers, and 193 individuals with high or low 16S abundances. Significantly elevated viral loads were observed at multiple 194 sampling time points for pneumococcal carriers when compared with noncarriers (Fig. 3A). Individuals with 195 high 16S abundances also displayed significantly increased viral loads at multiple sampling events when 196 compared with individuals with low 16S abundances (Fig. 3B). We subsequently modelled longitudinal 197 trajectories of log-transformed viral loads using linear mixed-effects modelling. Trajectories were estimated 198 from positive samples by censoring measurements with *Egene* C_as 40 or higher. We did not observe significant 199 differences in longitudinal viral load trajectories between pneumococcal carriers versus noncarriers (Fig. S6A-200 **B**), and between individuals with high versus low 16S abundances (**Fig. S6C-D**). 201

DISCUSSION 202

Interplay between respiratory viruses and pneumococcus are often synergistic drivers of respiratory infections 203 [8, 30]. In the current study, we investigated whether associations exist between SARS-CoV-2 infection and 204 pneumococcal carriage among children and non-elderly adults. 205

206

We observed high rates of pneumococcal carriage within households during nationwide implementation of 207 NPIs in the Netherlands in 2020/2021 [31]. Despite high coinfection rates we have found insufficient evidence 208 for a strong impact of SARS-CoV-2 infection on pneumococcal carriage rates and pneumococcal abundances. 209 However, pneumococcal carriers exhibited an increased risk of SARS-CoV-2 infection and delayed viral 210 clearance. Delayed viral clearance was also observed among individuals with high 16S abundances yet we 211 observed no association between 16S abundances and SARS-CoV-2 infection rates. Both pneumococcal 212 carriers and individuals with high 16S abundances exhibited increased SARS-CoV-2 viral loads at multiple 213 sampling events. However, differences in longitudinal viral load trajectories among pneumococcal carriers or 214 individuals with high 16S abundances were not significant. 215

216

Despite the imposition of NPIs and a decline in seasonal respiratory virus circulation during the study period 217 [32] there was a substantial presence of pneumococcal carriage. Our observations are in line with reports by 218 others [15, 20], suggesting that pneumococcal carriage prevalence rates did not decline during the COVID-19 219 pandemic and during NPIs. In contrast, the incidence of IPD dropped sharply during the 2020/2021 influenza 220 season [13-15]. Danino et al. have attributed this decline in IPD to a drop in seasonal respiratory virus 221 circulation following the imposition of NPIs and travel restrictions across countries [15]. 222

223

Pneumococcal carriage rates were relatively constant throughout the study period. SARS-CoV-2 infected 224 individuals exhibited elevated pneumococcal abundances and 16S abundances at several time points. 225 However, no significant differences between SARS-CoV-2 infected and uninfected individuals were observed 226 for relative pneumococcal abundances. Moreover, we have observed no substantial shift in sample serotype 227 composition during the study period. Collectively, these observations suggest no marked impact of SARS-228 CoV-2 infection unique to pneumococcal colonization. Our findings are in line with studies describing that 229 co-infections of SARS-CoV-2 and pneumococcus are uncommon [17, 33]. 230

231

We performed Cox regression analysis to study possible interactions between SARS-CoV-2 and 232 pneumococcus. As such, we modelled the impact of pneumococcal abundances independently from 16S 233 abundances on SARS-CoV-2 infection rates and on SARS-CoV-2 infection clearance rates. Pneumococcal 234 abundances were associated with an increased risk for SARS-CoV-2 infection, while there was insufficient 235 evidence for an altered risk among individuals with high 16S abundances. High cumulative hazard rates among 236 children but not among adults indicated that the relationship between pneumococcal abundances and SARS-237 CoV-2 infection was primarily associated with children. 238

In an observational study among older adults vaccination with PCV13 was reported to the reduce the risk of 239 COVID-19 diagnosis, COVID-19 hospitalization and fatal COVID-19 outcome [17], suggesting that PCV13 240 vaccine-type pneumococcal carriage could predispose older adults to adverse outcomes associated with 241 COVID-19. Another study among adults reported an increased odds of SARS-CoV-2 infection among 242 pneumococcus-positive adults attending a COVID-19 testing clinic, yet in the same study pneumococcus-243 positive adults attending an outreach facility did not exhibit an increased odds of SARS-CoV-2 infection [34], 244 suggesting that the association between pneumococcal carriage and SARS-CoV-2 may be non-causal. While 245 previous studies focused on older individuals [17, 34], we investigated possible viral-bacterial interactions in 246 children and non-elderly adults. Although we find that pneumococcal abundances were associated with 247 increased SARS-CoV-2 infection rates, due to the limit number of events we cannot exclude that the reported 248 association may have been attributable to confounding factors. 249

250

Findings from a study in the United Kingdom have suggested that IgA and CD4⁺ T-cell responses to SARS-251 CoV-2 may be impaired among pneumococcal carriers [35]. Of note, CD4⁺ T-cell mediated responses are also 252 critical for clearance of pneumococcal colonization. Impairment of immune responses to SARS-Cov-2 also 253 prolongs viral infection [36]. Consequently, one would expect delayed clearance of SARS-CoV-2 infection 254 among pneumococcal carriers. Cox regression analysis of SARS-CoV-2 infection clearance rates indicated 255 that high pneumococcal abundances were indeed associated with delayed clearance of SARS-CoV-2 infection. 256 However, since high 16S abundances were also associated with delayed viral clearance, we do not find an 257 association unique to pneumococcus. 258

259

High 16S abundances of the URT have previously been linked to dysbiosis of the URT microbiota in adults with community-acquired pneumonia [37]. The observed association between increased 16S abundances and delayed SARS-CoV-2 infection clearance in this study may therefore result from COVID-19 induced URT microbiome dysbiosis. Our observation is also in line with a study describing distinct URT microbiome composition profiles among hospitalized COVID-19 patients when compared with healthy individuals, which were linked to URT microbiota dysbiosis and were shown to correlate with COVID-19 severity [38].

266

Among study participants infected with SARS-CoV-2 at enrolment, pneumococcal carriers and individuals 267 with high 16S abundances exhibited elevated SARS-CoV-2 viral loads at multiple sampling events, suggesting 268 that presence of pneumococcal carriage could have impact SARS-CoV-2 infection progression. Modelling of 269 longitudinal viral load patterns indicated that pneumococcal carriage was not associated with altered viral load 270 dynamics. Since elevated SARS-CoV-2 viral loads were observed among pneumococcal carriers and 271 individuals with high 16S abundances, it appears likely that these findings are also related to COVID-19 272 induced URT microbiota dysbiosis rather than exacerbation of SARS-CoV-2 infection due to pneumococcal 273 colonization. Of note, since this study was conducted at a time prior to the emergence of SARS-CoV-2 variants 274

of concern (VOCs) in the Netherlands, interferences we observed could be affected by higher transmissibility
of VOCs [31].

277

As this study was primarily designed to evaluate the use of saliva in monitoring SARS-CoV-2 and to study 278 SARS-CoV-2 household transmission dynamics [21], it has number of limitations for analysis of 279 280 pneumococcal carriage and interactions between pneumococcus and SARS-CoV-2. The age group at greatest risk for both pneumococcal disease and COVID-19 was not included in this study, as such interactions 281 between pneumococcus and SARS-CoV-2 specific for older age have been missed. The number of secondary 282 cases of SARS-CoV-2 infections after the first sampling event were low, limiting the statistical power 283 available for Cox regression analysis of SARS-CoV-2 infection. Moreover, the overall study size limited our 284 ability to adjust for potential confounding factors in Cox regression analysis. Pneumococcal carriage episodes 285 may have been missed due to the omission of a culture-enrichment procedure for pneumococcal detection 286 [39]. 287

288

In conclusion, in a cohort of children and non-elderly adults we observed high rates of pneumococcal carriage and coinfections with SARS-CoV-2. While we find insufficient evidence for a strong impact of SARS-CoV-2 infection on pneumococcal carriage rates and pneumococcal abundances, we do observe an increased risk of SARS-CoV-2 infection among pneumococcal carriers, children in particular. Moreover, individuals with high pneumococcal abundances or 16S abundances exhibited delayed SARS-CoV-2 infection clearance and elevated viral loads, suggesting dysbiosis of the URT microbiome following SARS-CoV-2 infection. medRxiv preprint doi: https://doi.org/10.1101/2023.02.20.23286191; this version posted February 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

295 AUTHOR CONTRIBUTIONS

W.R.M., E.A.M.S., M.A.v.H. and K. T. contributed to the conception and design of the study. D.E., J.v.V.,
G.P., L.M.K., S.v.L., S.M.E. and R.M. participated in acquisition of data. R.M., D.E., S.v.L. and S.M.E.
coordinated the laboratory analyses. W.R.M., R.M., M.A.N., J.v.V., L.M.K. and K.T. were responsible for
data analyses and interpretation. W.R.M., M.A.N., L.M.K. and J.v.V. verified the underlying data W.R.M.,
R.M. and K.T. wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

302 ACKNOWLEDGEMENTS

We thank all the participants for their contribution to the study. We thank the team of the Public Health Services Kennemerland, for providing information to the (potential) participants; the Regional Public Health Laboratory (Streeklab) Kennemerland for laboratory analyses; and the research team of the Spaarne Gasthuis Academy, particularly Greetje van Asselt, Jacqueline Zonneveld, Sandra Kaamer van Hoegee, and Mara van Roermund for their hard work and Coen Lap for his efforts concerning the continuation of the SARSLIVA study. We thank the laboratory team from the virology department at National Institute for Public Health and the Environment (RIVM). We thank Tessa Nieuwenhuijsen for her assistance in the laboratory. medRxiv preprint doi: https://doi.org/10.1101/2023.02.20.23286191; this version posted February 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

310 **REFERENCES**

- 3121.Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in313pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis **2008**; 198(7): 962-70.
- 2. Grijalva CG, Griffin MR, Edwards KM, et al. The role of influenza and parainfluenza infections in
- nasopharyngeal pneumococcal acquisition among young children. Clin Infect Dis **2014**; 58(10): 1369-76.
- Karppinen S, Terasjarvi J, Auranen K, et al. Acquisition and Transmission of Streptococcus pneumoniae Are
 Facilitated during Rhinovirus Infection in Families with Children. Am J Respir Crit Care Med **2017**; 196(9):
 1172-80.
- DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER. Dynamics of Bacterial Colonization With Streptococcus
 pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic
 Viral Upper Respiratory Tract Infection. Clin Infect Dis **2018**; 66(7): 1045-53.
- Thors V, Christensen H, Morales-Aza B, et al. High-density Bacterial Nasal Carriage in Children Is Transient
 and Associated With Respiratory Viral Infections-Implications for Transmission Dynamics. Pediatr Infect Dis J
 2019; 38(5): 533-8.
- Miellet WR, van Veldhuizen J, Nicolaie MA, et al. Influenza-like Illness Exacerbates Pneumococcal Carriage in
 Older Adults. Clin Infect Dis **2020**.
- Ramos-Sevillano E, Wade WG, Mann A, et al. The Effect of Influenza Virus on the Human Oropharyngeal
 Microbiome. Clin Infect Dis **2019**; 68(12): 1993-2002.
- 3298.Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper330respiratory tract. PLoS Pathog **2013**; 9(1): e1003057.
- McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014;
 12(4): 252-62.
- 33310.Vissers M, Ahout IM, van den Kieboom CH, et al. High pneumococcal density correlates with more mucosal334inflammation and reduced respiratory syncytial virus disease severity in infants. BMC Infect Dis **2016**; 16:335129.
- Howard LM, Zhu Y, Griffin MR, et al. Nasopharyngeal Pneumococcal Density during Asymptomatic
 Respiratory Virus Infection and Risk for Subsequent Acute Respiratory Illness. Emerg Infect Dis 2019; 25(11):
 2040-7.
- 33912.Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs human innate340immune control of pneumococcus. Nat Immunol **2018**; 19(12): 1299-308.
- Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health **2021**; 3(6): e360-e70.
- Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic
 on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory
 Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England. Clin Infect Dis 2021;
 72(5): e65-e75.
- Danino D, Ben-Shimol S, van der Beek BA, et al. Decline in Pneumococcal Disease in Young Children During
 the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal
 Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis
 2022; 75(1): e1154-e64.
- Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients
 hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a
 multicentre, prospective cohort study. Lancet Microbe 2021; 2(8): e354-e65.
- Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of COVID-19 among older adults receiving
 pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2
 in the respiratory tract. J Infect Dis 2021.
- 35918.Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with360COVID-19 an evidence based guideline. Clin Microbiol Infect **2021**; 27(1): 61-6.
- 19. Cucchiari D, Pericas JM, Riera J, et al. Pneumococcal superinfection in COVID-19 patients: A series of 5 cases.
 362 Med Clin (Engl Ed) **2020**; 155(11): 502-5.
- 36320.Willen L, Ekinci E, Cuypers L, Theeten H, Desmet S. Infant Pneumococcal Carriage in Belgium Not Affected by364COVID-19 Containment Measures. Front Cell Infect Microbiol **2021**; 11: 825427.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.20.23286191; this version posted February 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Kolodziej LM, van Lelyveld SF, Haverkort ME, et al. High SARS-CoV-2 Household Transmission Rates Detected
 by Dense Saliva Sampling.
- Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
 Euro Surveill **2020**; 25(3).
- Trzcinski K, Bogaert D, Wyllie A, et al. Superiority of trans-oral over trans-nasal sampling in detecting
 Streptococcus pneumoniae colonization in adults. PLoS One **2013**; 8(3): e60520.
- Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays
 targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 2007; 45(8): 2460-6.
- Miellet WR, van Veldhuizen J, Litt D, et al. It Takes Two to Tango: Combining Conventional Culture With
 Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal
 Serogroup/Serotype Determination in Carriage. Front Microbiol **2022**; 13: 859736.
- Miellet WR, van Veldhuizen J, Litt D, et al. A Spitting Image: Molecular Diagnostics Applied to Saliva Enhance
 Detection of Streptococcus pneumoniae and Pneumococcal Serotype Carriage. Unpublished results.
- Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability
 Research. J Chiropr Med **2016**; 15(2): 155-63.
- Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical
 measurement. Lancet **1986**; 1(8476): 307-10.
- Hothorn T, Hornik K, van de Wiel MA, Zeileis A. Implementing a Class of Permutation Tests: The coin Package
 Journal of Statistical Software **2008**; 28(8).
- 30. Li Y, Peterson ME, Campbell H, Nair H. Association of seasonal viral acute respiratory infection with
 pneumococcal disease: a systematic review of population-based studies. BMJ Open **2018**; 8(4): e019743.
- Han AX, Kozanli E, Koopsen J, et al. Regional importation and asymmetric within-country spread of SARS CoV-2 variants of concern in the Netherlands. Elife **2022**; 11.
- Reukers D, van Asten L, Brandsema P, et al. Annual report Surveillance of COVID-19, influenza and other
 respiratory infections in the Netherlands: winter 2020/2021. Surveillance van COVID-19, griep en andere
 luchtweginfecties: winter 2020/2021: Rijksinstituut voor Volksgezondheid en Milieu RIVM, **2021**.
- 33. Aykac K, Ozsurekci Y, Cura Yayla BC, et al. Pneumococcal carriage in children with COVID-19. Hum Vaccin
 Immunother **2021**; 17(6): 1628-34.
- 39334.Parker AM, Jackson N, Awasthi S, et al. Association of upper respiratory Streptococcus pneumoniae394colonization with SARS-CoV-2 infection among adults. Clin Infect Dis **2022**.
- 39535.Mitsi E, Reine J, Urban BC, et al. Streptococcus pneumoniae colonization associates with impaired adaptive396immune responses against SARS-CoV-2. J Clin Invest **2022**.
- 36. Walsh KA, Spillane S, Comber L, et al. The duration of infectiousness of individuals infected with SARS-CoV-2.
 J Infect 2020; 81(6): 847-56.
- 39937.de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, et al. Dysbiosis of upper respiratory tract microbiota in400elderly pneumonia patients. ISME J **2016**; 10(1): 97-108.
- 40138.Merenstein C, Liang G, Whiteside SA, et al. Signatures of COVID-19 Severity and Immune Response in the402Respiratory Tract Microbiome. mBio 2021; 12(4): e0177721.
- Miellet WR, van Veldhuizen J, Litt D, et al. It Takes Two to Tango: Combining Conventional Culture with
 Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal
 Corregroup / Corptume determination in Corrigon mod Pvin 2021
- 405 Serogroup/Serotype determination in Carriage. medRxiv **2021**.
- 406

Table 1 : Study participant characteristics

	Overall	SARS-CoV-2	SARS-CoV-2	S. pneumoniae	S. pneumoniae	Co-infected
Group		infected	uninfected	carriers	noncarriers	
	(n=274)	(n=177)	(n=97)	(n=160)	(n=114)	(n=106)
median age, years (range)	32 (0-64)	32 (0-63)	30 (1-64)	17 (1-63)	42 (0-64)	22 (1-63)
age group, n (%)						
< 12	51 (18.6)	29 (16.4)	22 (22.7)	45 (28.4)	6 (5.3)	25 (23.6)
12-17	47 (17.2)	31 (17.5)	16 (16.5)	36 (22.5)	11 (9.6)	25 (23.6)
18-39	65 (23.7)	49 (27.7)	16 (16.5)	31 (19.4)	34 (29.8)	25 (23.6)
40-49	74 (27.0)	44 (24.9)	30 (30.9)	35 (21.9)	39 (34.2)	21 (19.8)
50-65	37 (13.5)	24 (13.6)	13 (13.4)	13 (8.1)	24 (21.1)	10 (9.4)
sex, n (%)						
male	135 (49.3)	87 (49.2)	48 (49.5)	85 (53.1)	50 (43.9)	56 (52.8)
female	139 (50.7)	90 (50.8)	49 (50.5)	75 (46.9)	64 (56.1)	50 (47.2)
comorbidities, n (%)	30 (10.9)	14 (7.9)	16 (16.5)	14 (8.8)	16 (14.0)	7 (6.6)
symptomatic, n (%)	167 (60.9)	139 (78.5)	28 (28.9)	96 (60.0)	71 (62.3)	78 (73.6)
median household size, n (range)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)
presence of a child aged <5 years	54 (19.7)	37 (20.9)	17 (17.5)	48 (30.0)	6 (5.3)	31 (29.2)
in a household, n (%)						

409 Table S1: Rates across study observation period

	•		-							
Group	T=1	T=3	T=5	T=7	T=10	T=14	T=21	T=28	T=35	T=42
SARS-CoV-2 infection, n (%)	153	159	151	150	138	115	77	56	22	17
	(55.8)	(58.0)	(55.1)	(54.7)	(50.4)	(42.0)	(28.1)	(20.4)	(8.0)	(6.2)
pneumococcal carriage, n (%)	92	107	114	115	117	114	106	118	120	104
	(33.6)	(39.1)	(41.6)	(42.0)	(42.7)	(41.6)	(38.7)	(43.1)	(43.8)	(38.0)

410

411 Observed SARS-CoV-2 infection and *S. pneumoniae* carriage rates across the six week study period among 274 individuals, including 98 children and 176 non-elderly adults.

412 Table S2 : SARS-CoV-2 infection acquisition model selection

Model	Coefficient (95% CI)	<i>P</i> -value	AIC
Model I:			188.13
log-transformed <i>piaB</i> abundance	1.14 (0.99 – 1.31)	0.065	
Model II:			191.10
log-transformed 16S abundance	0.87 (0.59 – 1.29)	0.487	
Model III:			189.55
log-transformed <i>piaB</i> abundance	1.14 (0.99 – 1.31)	0.096	
log-transformed 16S abundance	0.86 (0.57 – 1.27)	0.686	
Model IV:			189.55
log-transformed <i>piaB</i> abundance	1.14 (1.01 – 1.29)	0.038	
log-transformed 16S abundance	0.86 (0.58 – 1.27)	0.673	

413 AIC: Akaike information criterion, Number of included events were n=24.

415 Table S3 : SARS-CoV-2 infection clearance model selection

Model	Coefficient (95% CI)	<i>P</i> -value	AIC
Model I:			1343.01
log-transformed <i>piaB</i> abundance	$0.90\ (0.85 - 0.96)$	0.002	
Model II:			1331.37
log-transformed 16S abundance	0.71 (0.62 - 0.82)	< 0.0001	
Model III:			1328.12
log-transformed piaB abundance	$0.92\;(0.86-0.98)$	< 0.001	
log-transformed 16S abundance	0.73 (0.64 - 0.86)	< 0.001	
Model IV*:			1326.15
log-transformed <i>piaB</i> abundance for T<21	$0.90\ (0.82 - 0.99)$	0.025	
log-transformed <i>piaB</i> abundance for T \geq 21	0.93 (0.85 - 1.02)	0.149	
log-transformed 16S abundance for T<21	$0.65\ (0.55-0.78)$	< 0.0001	
log-transformed 16S abundance for T≥21	0.89 (0.70 - 1.13)	0.343	

416 AIC: Akaike information criterion. Number of included events were n=192. T: sampling event wherein T<21 indicates the 0-21 subinterval and T \geq 21 indicates the 21-42 interval.

*: Based on exploratory analysis, we allowed some flexibility in the modeling by estimating time-varying effects of covariates. We divided the follow-up interval in two subintervals [0-21)

418 and [21-42] and estimated piece-wise constant regression coefficients







Figure 2: Alluvial diagram displaying longitudinal changes across the study period in participant status for SARS-CoV-2 infection and pneumococcal carriage among n=274 participants. Infected noncarriers, infected carriers, uninfected noncarriers are colored in blue, red, yellow and green, respectively. Percentages of groups are shown in bars. The right y-axis indicates the number of individuals.



Figure 3: Boxplots of SARS-CoV-2 viral loads from individuals positive for SARS-CoV-2 since study onset (t=1) and stratified by pneumococcal carriage status (A) and overall bacterial abundance (B). Viral loads were compared blocked by age group (< 18 years old or \ge 18 years old) with a permutation test equivalent of Mann-Whitney U test. Pneumococcal carriers display significantly increased viral loads at day 3, 5, 10 and 28 of study period when compared with noncarriers. Individuals with increased bacterial abundance display significantly increased viral loads at day 1, 5, 7, 10 and 21 of study period when compared with reduced bacterial abundance. Medians are indicated by a solid line in a boxplot.



Figure S1: Scatter plot displaying C_q **measurements for** *piaB* and *lytA* **targets for all individuals at individual sampling events.** Red and blue dots represent samples positive and negative for *S. pneumoniae*, respectively. Samples were considered to be positive for *S. pneumoniae* when Cq for both *piaB* and *lytA* were below 40 C_q, the C_q threshold is indicated by dashed lines. Numbers coloured red indicate the number of samples classified as positive for pneumococcus and black. ICC: intraclass correlation coefficient - a single score intraclass correlation coefficient with two-way model (consistency) was used for reliability analysis. ICC values <0.50, 0.50-0.75, 0.75-0.90 and >0.90 are indicative of poor, moderate, good, and excellent reliability, respectively.



Figure S2: (**A**) The survival probability of time to infection acquisition estimated by the non-parametric Kaplan-Meier estimator (in grey) and model-based (in black) and the respective 95% confidence intervals. While the two survival curves for children are virtually the same up to day 5, after day 5 the model-based curve slightly overestimates the non-parametric estimator. This difference is most likely due to the uncertainty of estimation caused by the reduced number of events after day 5 in our sample. (**B**) Predicted survival probabilities based on the Cox proportional hazards model (model IV of Table S2), stratified by age group, were compared for a participant with a relatively high pneumococcal abundance (high piaB) and average 16S abundance (overall bacterial abundance), represented by the dashed curves and a participant with relatively low pneumococcal abundance (low *piaB*) and average 16S abundance, represented by continuous curves. The continuous curves decrease at a lower rate than the dotted counterparts, illustrating the adverse effect of high *piaB* values on the rate of infection acquisition. Curves from children and adults are depicted in black and grey colours, respectively.



Figure S3: (A) The survival probability of time to infection acquisition estimated by the non-parametric Kaplan-Meier estimator (in grey) and model-based (in black) and the respective 95% confidence intervals. The two sets of curves are in agreement with each other, both for children and for adults. (B) Predicted survival probabilities based on the Cox proportional hazards model (model IV of Table S3), stratified by age group, were compared for a participant with a relatively high pneumococcal abundance (high *piaB*) and average 16S abundance (overall bacterial abundance), represented by the dashed curves and a participant with relatively low pneumococcal abundance (low piaB) and average 16S abundance, represented by continuous curves. The continuous curves decrease at a higher rate than the dotted counterparts, illustrating the impairing effect of high *piaB* values on SARS-CoV-2 infection clearance rates. Curves from children and adults are depicted with black and grey colours, respectively.



Figure S4: (A) Pneumococcal abundances (*piaB*) of individuals that are identified as carrier for \geq 1 sampling events, stratified by COVID-19 status. (B) Overall bacterial abundances from any individual irrespective of pneumococcal carriage status, stratified by COVID-19 status. The colour purple indicates positivity for SARS-CoV-2 infection. None of the sampling events display a significant difference in either pneumococcal abundances or overall bacterial abundance between individuals with or without a SARS-CoV-2 infection. A permutation test equivalent of the Mann-Whitney U test was used to compare abundances of SARS-CoV-2 infected and uninfected individuals while blocking by age groups (< 18 years old or \geq 18 years old).



Figure S5: Stacked bardiagrams of serotype sample composition per time point for (A) children) and (B) adults. Analysis was limited to qPCR-targeted serotypes. The percentage of serotypes or serogroups among pneumococcus positive samples are shown. Percentages are calculated per sampling event for children (<18 year olds) and adults (\geq 18 year olds) separately. Results are limited to serotype-specific or serogroup-specific qPCR assays that produced atleast one or more positive samples.



Figure S6: Longitudinal SARS-CoV-2 viral load trajectories of pneumococcal carriers (A & B), and individuals with 16S abundance (C & D) were analyzed with linear mixed effects models. Data from children (A & C) and adults (B & D) are modeled separately. Shaded areas indicate the 95% confidence interval of model estimates and the lines indicate the coefficients of model estimates. Censoring was applied to samples with a viral load of \geq 40 Cq for the *Egene*. Pneumococcal carriers (A & B) are colored in red and noncarriers in blue. All individuals were positive for SARS-CoV-2 at T=1. Individuals with 16S abundances higher or equal to the median 16S abundance at T=1 are colored in green and individuals with 16S abundances below the median 16S abundance at T=1 are colored in yellow. None of the tested model exhibited significant differences in viral load trajectories for any of the analyzed groups.

SUPPLEMENTAL TEXT

Molecular Detection of Pneumococcal Serotypes

qPCR-based Serotyping of Saliva Samples

Per individual, DNA was extracted from pools of samples exclusively positive for *S. pneumoniae* and collected from a single person. For each individual, samples positive for *S. pneumoniae* were pooled in equal ratio and 200 µl of the pool (for individuals positive for *S. pneumoniae* only once, 200 µl of a single sample) was processed for nucleic acids extraction as described above. Serotype composition of pools was determined using a panel of primers and probes targeting serotypes 1, 3, 8, 14, 16F, 19A, 19F, 20, 21, 23A, 23B, 23F, 34 and 38, and serogroups 6A/B/C/D, 7A/F, 9A/L/N/V, 10A/B, 11A/D, 12A/B/C/F, 15A/B/C/F, 18A/B/C/F, 22A/F, 33A/F, 35B/C. When a pool of samples was positive for a serotype-specific or serogroup-specific qPCR assay all individual samples were also tested for that particular assay.

Evaluation of Diagnostic Specificity of Serotype/Serogroup-specific qPCR Assays in Saliva

Bland-Altman analysis was conducted to evaluate the specificity of serotype/serogroup-specific qPCR assays. Per sampling event, the upper limit of agreement between *piaB* and *lytA* was used as an a priori acceptible limit for agreement between serotype quantification and *piaB* or *lytA*. These limits ranged between 2.79 to 3.72 and were used to identify putative nonreliable results that exhibited strongly increased quantification of serotypes or serogroups when compared with quantification of *piaB* or *lytA*. In this analysis, serotypes 21 and 23A, and serogroups 9A/L/N/V, 12A/B/F, 33A/F and 35B/C were overrepresented and therefore all results from these assays were excluded from further analysis. Prior to exclusion of these qPCR assays, the mean ICC between dominantly ranked serotypes and *piaB* was 0.61, whereas after exclusion the mean ICC was 0.70.